Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin

[1]  E. Milbrandt,et al.  Use it or lose it! , 2008, Critical care medicine.

[2]  E. Hol,et al.  The neuronal ubiquitin-proteasome system: Murine models and their neurological phenotype , 2008, Progress in Neurobiology.

[3]  Peipei Ping,et al.  Mammalian Proteasome Subpopulations with Distinct Molecular Compositions and Proteolytic Activities* , 2007, Molecular & Cellular Proteomics.

[4]  Howard Schulman,et al.  Global changes to the ubiquitin system in Huntington's disease , 2007, Nature.

[5]  E. Hol,et al.  Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease , 2007, Journal of Cell Science.

[6]  J. Collinge,et al.  Disease-associated prion protein oligomers inhibit the 26S proteasome. , 2007, Molecular cell.

[7]  O. Zolk,et al.  Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. , 2007, Biochemical and biophysical research communications.

[8]  Jürgen Götz,et al.  β‐Amyloid treatment of two complementary P301L tau‐expressing Alzheimer's disease models reveals similar deregulated cellular processes , 2006, Proteomics.

[9]  T. Bonhoeffer,et al.  A Balance of Protein Synthesis and Proteasome-Dependent Degradation Determines the Maintenance of LTP , 2006, Neuron.

[10]  W. Scheper,et al.  Ubiquitin proteasome system as a pharmacological target in neurodegeneration , 2006, Expert review of neurotherapeutics.

[11]  O. Vitolo,et al.  Ubiquitin Hydrolase Uch-L1 Rescues β-Amyloid-Induced Decreases in Synaptic Function and Contextual Memory , 2006, Cell.

[12]  Masaaki Komatsu,et al.  Loss of autophagy in the central nervous system causes neurodegeneration in mice , 2006, Nature.

[13]  C. Almeida,et al.  β-Amyloid Accumulation Impairs Multivesicular Body Sorting by Inhibiting the Ubiquitin-Proteasome System , 2006, The Journal of Neuroscience.

[14]  G. Leuba,et al.  Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies , 2006, Neurology.

[15]  I. Mook‐Jung,et al.  Amyloid peptide attenuates the proteasome activity in neuronal cells , 2005, Mechanisms of Ageing and Development.

[16]  A. Brice,et al.  Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function , 2005, Journal of neurochemistry.

[17]  E. Hol,et al.  The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1. , 2005, Trends in molecular medicine.

[18]  Mayur B. Patel,et al.  CYTOSOLIC UBIQUITIN AND UBIQUITYLATION RATES IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS DURING SEPSIS , 2005, Shock.

[19]  R. Tanzi,et al.  The genetic epidemiology of neurodegenerative disease. , 2005, The Journal of clinical investigation.

[20]  T. Montine,et al.  The FASEB Journal express article 10.1096/fj.04-3210fje. Published online March 3, 2005. ©2005 FASEB , 2022 .

[21]  J. M. Lee,et al.  Tau phosphorylation increases in symptomatic mice overexpressing A30P α-synuclein , 2005, Experimental Neurology.

[22]  E. Bennett,et al.  Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. , 2005, Molecular cell.

[23]  E. Hol,et al.  Molecular misreading: the frequency of dinucleotide deletions in neuronal mRNAs for β-amyloid precursor protein and ubiquitin B , 2005, Neurobiology of Aging.

[24]  N. Gonatas,et al.  Effect of ubiquitin expression on neuropathogenesis in a mouse model of familial amyotrophic lateral sclerosis , 2005, Neuropathology and applied neurobiology.

[25]  J. L. Rekart,et al.  Post-translational protein modification as the substrate for long-lasting memory , 2005, Trends in Neurosciences.

[26]  E. Hol,et al.  Protein quality control in Alzheimer's disease by the ubiquitin proteasome system , 2004, Progress in Neurobiology.

[27]  Yong-Keun Jung,et al.  Alzheimer's disease meets the ubiquitin-proteasome system. , 2004, Trends in molecular medicine.

[28]  J. H. Boo,et al.  Profiling proteins related to amyloid deposited brain of Tg2576 mice , 2004, Proteomics.

[29]  Susumu Tonegawa,et al.  Translational Regulatory Mechanisms in Persistent Forms of Synaptic Plasticity , 2004, Neuron.

[30]  G. Vattemi,et al.  Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers , 2004, Neurology.

[31]  R. Roos,et al.  Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. , 2004, Human molecular genetics.

[32]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[33]  S. Weintraub,et al.  Proteomic identification of specific oxidized proteins in ApoE-knockout mice: relevance to Alzheimer's disease. , 2004, Free radical biology & medicine.

[34]  A. Lees,et al.  Failure in heat-shock protein expression in response to UBB+1 protein in progressive supranuclear palsy in humans , 2004, Neuroscience Letters.

[35]  A. Bruce-Keller,et al.  Analysis of gene expression in neural cells subject to chronic proteasome inhibition. , 2004, Free radical biology & medicine.

[36]  Eckart D Gundelfinger,et al.  Proteomics Analysis of Rat Brain Postsynaptic Density , 2004, Journal of Biological Chemistry.

[37]  G. Demartino,et al.  Aggregate formation in the spinal cord of mutant SOD1 transgenic mice is reversible and mediated by proteasomes , 2003, Journal of neurochemistry.

[38]  E. Hol,et al.  Disease‐specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  E. Hol,et al.  Frameshifted β-Amyloid Precursor Protein (APP+1) Is a Secretory Protein, and the Level of APP+1 in Cerebrospinal Fluid Is Linked to Alzheimer Pathology* , 2003, Journal of Biological Chemistry.

[40]  Aaron Ciechanover,et al.  The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.

[41]  S. Kim,et al.  Essential Role of E2-25K/Hip-2 in Mediating Amyloid-β Neurotoxicity , 2003 .

[42]  B. Shen,et al.  Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A , 2003, Oncogene.

[43]  E. Hol,et al.  Alzheimer's associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression , 2003, Journal of neurochemistry.

[44]  Vidya N. Nukala,et al.  Characterization of chronic low‐level proteasome inhibition on neural homeostasis , 2003, Journal of neurochemistry.

[45]  K. Davies,et al.  Selective degradation of oxidatively modified protein substrates by the proteasome. , 2003, Biochemical and biophysical research communications.

[46]  Visith Thongboonkerd,et al.  Proteomic identification of nitrated proteins in Alzheimer's disease brain , 2003, Journal of neurochemistry.

[47]  R. Nitsch,et al.  Proteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's disease , 2003, Journal of neurochemistry.

[48]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[49]  K. Davies,et al.  Ubiquitin Conjugation Is Not Required for the Degradation of Oxidized Proteins by Proteasome* , 2003, The Journal of Biological Chemistry.

[50]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[51]  B. Halliwell,et al.  Proteasomal dysfunction induced by 4‐hydroxy‐2,3‐trans‐nonenal, an end‐product of lipid peroxidation: a mechanism contributing to neurodegeneration? , 2002, Journal of neurochemistry.

[52]  L. Serpell,et al.  Proteasomal degradation of tau protein , 2002, Journal of neurochemistry.

[53]  D. Butterfield,et al.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase‐related protein 2, α‐enolase and heat shock cognate 71 , 2002, Journal of neurochemistry.

[54]  N. Cairns,et al.  Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. , 2002, Biochemical and biophysical research communications.

[55]  S. Shimohama,et al.  Proteomic Profiling and Neurodegeneration in Alzheimer's Disease , 2002, Neurochemical Research.

[56]  D. Butterfield,et al.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. , 2002, Free radical biology & medicine.

[57]  D. Selkoe,et al.  The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics , 2002, Science.

[58]  H. Cai,et al.  Genetically engineered mouse models of neurodegenerative diseases , 2002, Nature Neuroscience.

[59]  E. Hol,et al.  Molecular misreading of the ubiquitin B gene and hepatic mallory body formation. , 2002, Gastroenterology.

[60]  H. Geerts,et al.  Proteomics analysis of the neurodegeneration in the brain of tau transgenic mice , 2002, Proteomics.

[61]  E. Hol,et al.  Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation , 2002, The Journal of cell biology.

[62]  T. Hudson,et al.  Control genes and variability: absence of ubiquitous reference transcripts in diverse mammalian expression studies. , 2002, Genome research.

[63]  P. Rehbinder,et al.  Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units , 2002, Laboratory animals.

[64]  F. Vandesande,et al.  Differential expression of brain proteins in glycogen synthase kinase‐3 transgenic mice: A proteomics point of view , 2002, Proteomics.

[65]  E. Hol,et al.  Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  K. Ashe.  Learning and memory in transgenic mice modeling Alzheimer's disease. , 2001, Learning & memory.

[67]  R. Faull,et al.  Proteomic analysis of the brain in Alzheimer’s disease: Molecular phenotype of a complex disease process , 2001, Proteomics.

[68]  G. Lynch,et al.  Rapid induction of intraneuronal neurofibrillary tangles in apolipoprotein E-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[69]  G. Nagle,et al.  Structure, localization and potential role of a novel molluscan trypsin inhibitor in Lymnaea. , 2001, European journal of biochemistry.

[70]  P M Kloetzel,et al.  Different proteasome subtypes in a single tissue exhibit different enzymatic properties. , 2000, Journal of molecular biology.

[71]  G. Feng,et al.  Imaging Neuronal Subsets in Transgenic Mice Expressing Multiple Spectral Variants of GFP , 2000, Neuron.

[72]  C. Pickart,et al.  Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[73]  W. Markesbery,et al.  Impaired Proteasome Function in Alzheimer's Disease , 2000, Journal of neurochemistry.

[74]  F. Leuven,et al.  Single and multiple transgenic mice as models for Alzheimer’s disease , 2000, Progress in Neurobiology.

[75]  A. Tsugita,et al.  Proteome analysis of mouse brain: Two‐dimensional electrophoresis profiles of tissue proteins during the course of aging , 2000, Electrophoresis.

[76]  J. Warrington,et al.  Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. , 2000, Physiological genomics.

[77]  C. Crews,et al.  Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[78]  Keiji Tanaka,et al.  4-Hydroxy-2-nonenal-mediated Impairment of Intracellular Proteolysis during Oxidative Stress , 1999, The Journal of Biological Chemistry.

[79]  R. King,et al.  Alzheimer’s Disease , 1999, Journal of neurochemistry.

[80]  F. Grosveld,et al.  Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. , 1998, Science.

[81]  Hee-Sup Shin,et al.  Mutant Mice and Neuroscience: Recommendations Concerning Genetic Background , 1997, Neuron.

[82]  Allan Collins,et al.  Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies , 1997, Psychopharmacology.

[83]  Pico Caroni,et al.  Overexpression of growth-associated proteins in the neurons of adult transgenic mice , 1997, Journal of Neuroscience Methods.

[84]  J. Hainfeld,et al.  Binding of Amyloid β Protein to the 20 S Proteasome* , 1997, The Journal of Biological Chemistry.

[85]  E. Kandel,et al.  Control of Memory Formation Through Regulated Expression of a CaMKII Transgene , 1996, Science.

[86]  T. Shibasaki,et al.  Ability of ubiquitin radioimmunoassay to discriminate between monoubiquitin and multi-ubiquitin chains. , 1996, Biochimica et biophysica acta.

[87]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[88]  W. V. Van Nostrand,et al.  Amyloid β-Protein Inhibits Ubiquitin-dependent Protein Degradation in Vitro(*) , 1995, The Journal of Biological Chemistry.

[89]  A. Goldberg,et al.  Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[90]  D. F. Swaab,et al.  Brain aging and Alzheimer's disease, “Wear and tear” versus “Use it or lose it” , 1991, Neurobiology of Aging.

[91]  R. Jaenisch,et al.  A generic intron increases gene expression in transgenic mice , 1991, Molecular and cellular biology.

[92]  D. Selkoe.  The molecular pathology of Alzheimer's disease , 1991, Neuron.

[93]  Y. Ihara,et al.  Ubiquitin is a component of paired helical filaments in Alzheimer's disease. , 1987, Science.

[94]  R. Thompson,et al.  Levels of immunoreactive aldolase C, creatine kinase-BB, neuronal and non-neuronal enolase, and 14-3-3 protein in circulating human blood cells. , 1984, Clinica chimica acta; international journal of clinical chemistry.

[95]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[96]  L. Sternberger,et al.  THE UNLABELED ANTIBODY ENZYME METHOD OF IMMUNOHISTOCHEMISTRY PREPARATION AND PROPERTIES OF SOLUBLE ANTIGEN-ANTIBODY COMPLEX (HORSERADISH PEROXIDASE-ANTIHORSERADISH PEROXIDASE) AND ITS USE IN IDENTIFICATION OF SPIROCHETES , 1970, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[97]  S. Barondes,et al.  Delayed and sustained effect of acetoxycycloheximide on memory in mice. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[98]  L. B. Flexner,et al.  Memory in Mice as Affected by Intracerebral Puromycin , 1963, Science.

[99]  D. Butterfield,et al.  Proteomics analysis of the Alzheimer's disease hippocampal proteome. , 2007, Journal of Alzheimer's disease : JAD.

[100]  Stephen Maren.  Neurobiology of Pavlovian fear conditioning. , 2001, Annual review of neuroscience.

[101]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[102]  C. Pickart,et al.  Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.

[103]  D. Swaab,et al.  Diminished neuronal metabolic activity in Alzheimer's disease , 1999, Journal of Neural Transmission.

[104]  K. Hendil,et al.  Human proteasomes analysed with monoclonal antibodies. , 1995, The Biochemical journal.